TP53 and non-small cell lung carcinoma: In addition, no differences in sensitivity to osimertinib were observed according to TP53 genotype in other EGFR-mutated NSCLC cell lines (HCC4006 and H1975) stably expressing various p53 mutant proteins (Supplementary Figs. 1d, e and 2c, d).